We report that patients with COVID-19 displaying distinct neurological disorders have undetectable or extremely low levels of SARS-CoV-2 RNA in the cerebrospinal fluid, indicating that viral clearance precede the neurological involvement. This finding points to the need for the development of more sensitive molecular tests and the investigation of other neurotropic pathogens to exclude concurrent neuroinfection.
Keywords: COVID-19; Cerebrospinal fluid; Neurological manifestations; RT-PCR; SARS-CoV-2 RNA.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.